

As required under MAS Notice 637 and in line with Basel III requirements, **Tables 1 and 2** are mandatory disclosures on Regulatory Capital using prescribed templates.

Table 1 shows the reconciliation between the Group's published consolidated balance sheet and the regulatory capital components. The balance sheet is expanded to identify and map to the regulatory capital components as set out in Table 2 (in the column "Reference").

The scope of consolidation for accounting and regulatory purposes is similar, except for subsidiaries that carry out insurance business are not consolidated for regulatory purpose. The list of the Group's major insurance subsidiaries can be found in the Annual Report. As at 30 Sep 2015, the total assets or total equities of each of these subsidiaries were less than S\$1 billion.

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 30 Sep 2015

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 30 Sep 2015	Delever elect	T	т
S\$ million	Balance sheet as per published financial statements	Under regulatory scope of consolidation	Reference
Equity			
Share capital and other capital	5,882		
of which: Paid-up ordinary shares	3,704	3,704	A
of which: Transitional: Ineligible AT1 capital instruments	832	832	B1
of which: AT1 capital instruments	1,346	1,346	B2
Retained earnings	15.025	14,927	C
Other reserves	9,299	9,269	D
Equity attributable to equity holders of the Bank	30,206	3,203	
Non-controlling interests	157		
of which: Transitional: Ineligible surplus NCI of bank subsidiaries	157	0	E1
of which: NCI that meets criteria for inclusion in		U	<u> </u>
		11	Fo
- CET1 capital			E2 E3
- AT1 capital		2	E3
- T2 capital	20.000	2	E4
Total equity	30,363		
Liabilities Describe and helmost of health	44.004		
Deposits and balances of banks	14,884		
Deposits and balances of non-bank customers	244,630		
Bills and drafts payable	563		
Other liabilities	13,069		
Debts issued	19,849	2 222	
of which: Transitional: Ineligible T2 capital instruments	2,893	2,893	F1
of which: T2 capital instruments	1,648	1,648	F2
Total liabilities	292,994		
Assets			
Cash, balances and placements with central banks	44,733		
Singapore Government treasury bills and securities	6,741		
Other government treasury bills and securities	11,253		
Trading securities	1,380		
Placements and balances with banks	27,600		
Loans to non-bank customers	199,587		
of which: Provisions eligible for inclusion in T2 capital		939	G
Investment securities ¹	10,356		
of which: Investment in PE/VC exceeding 20% shareholding or holding period		61	Н
Other assets ¹	13,729		
of which: Amount related to deferred tax assets (net of deferred tax liabilities, where permissible)		395	I
Investment in associates and joint ventures 1	1,101		
of which: Amount related to goodwill		3	J1
Investment properties	1,285		
Fixed assets	1,453		
Intangible assets	4,138		
of which: Amount related to goodwill		4,138	J2
Investments approved under s32 of the Banking Act and insurance subsidiaries			
of which: Ordinary shares subject to threshold deduction		532	K1
of which: AT1 capital instruments		4	K2
Indirect investments in own capital instruments	-	1	L
Total Assets	323,357		
	,		

Abbreviation: CET1: Common Equity Tier 1; AT1: Additional Tier 1; T2: Tier 2; PE/VC: Private Equity and Venture Capital

Note:

¹ This includes investments approved under s32 of the Banking Act such as equity investments in investee companies exceeding 10% shareholding





Table 2 lists the regulatory capital components and the corresponding regulatory adjustments. The columns: (a) 'Amount' refers to components of capital calculated in accordance with MAS Notice 637, effective 1 Jan 2013, (b) 'Amount subject to Pre-Basel III Treatment' refers to components of capital that are on transitional arrangement, otherwise would be fully applied towards the relevant tier of capital, and (c) 'Source' provides link to Table 1 by way of alphabetic / alphanumeric references, and cross-reference within the table by way of row number. Regulatory adjustments that are deducted against capital are reflected as positive numbers. Amounts less than \$500,000 in absolute terms are shown as "0".

Table 2 - Capital Components as at 30 Sep 2015

Table	e 2 - Capital Components as at 30 Sep 2015	T		
	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
	Common Equity Tier 1 capital: instruments and reserves	7 uno une	Troutmont	000.00
1	Paid-up ordinary shares and share premium (if applicable)	3,704		A
2	Retained earnings	14,927		C
3#	Accumulated other comprehensive income and other disclosed reserves	9,269		D
4	Directly issued capital subject to phase out from CET1	3,203		
-	(only applicable to non-joint stock companies)			
5	Minority interest that meets criteria for inclusion	11	(0)	E1+E2, -E1
6	Common Equity Tier 1 capital before regulatory adjustments	27,911	(0)	LITLZ, -LI
U	Common Equity Tier 1 capital: regulatory adjustments	27,911		
7	Valuation adjustment pursuant to Part VIII of MAS Notice 637	_		
8		_	2.494	J1+J2
	Goodwill, net of associated deferred tax liability	1,656	2,484	J1+J2
9#	Intangible assets, net of associated deferred tax liability	- 450	- 007	
10#	Deferred tax assets that rely on future profitability	158	237	I
11	Cash flow hedge reserve	-	-	
12	Shortfall of TEP relative to EL under IRBA	-	-	
13	Increase in equity capital resulting from securitisation transactions	-	-	
14	Unrealised fair value gains/losses on financial liabilities and derivative liabilities	-	-	
	arising from changes in own credit risk			
15	Defined benefit pension fund assets, net of associated deferred tax liability	-		
16	Investments in own shares	1		L
17	Reciprocal cross-holdings in ordinary shares of financial institutions	-		
18	Capital investments in ordinary shares of unconsolidated financial institutions	-		
	in which Reporting Bank does not hold a major stake			
19#	Investments in ordinary shares of unconsolidated major stake companies	213	319	K1
	approved under s32 of Banking Act (including insurance subsidiaries)			
	(amount above 10% threshold)			
20 [#]	Mortgage servicing rights (amount above 10% threshold)	-		
21#	Deferred tax assets arising from temporary differences	-		
	(amount above 10% threshold, net of related tax liability)			
22	Amount exceeding the 15% threshold	-		
23#	of which: investments in ordinary shares of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (including insurance subsidiaries)			
24#	of which: mortgage servicing rights	_		
25#	of which: deferred tax assets arising from temporary differences	_		
26	National specific regulatory adjustments	24		
26A	PE/VC investments in the form of ordinary shares, in excess of 20%	24	36	Н
20/1	of such capital investments			
26B	PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	0	0	Н
			-	11
26C	Capital deficits in subsidiaries and associates that are regulated financial institutions	-	-	
26D	Any other items which the Authority may specify	604		shortfall of row
27	Regulatory adjustments applied in calculation of CET1 Capital due to insufficient	604		shortfall of row
00	AT1 Capital to satisfy required deductions	0.057		36 over row 43
28	Total regulatory adjustments to CET1 Capital	2,657		
29	Common Equity Tier 1 capital (CET1)	25,254		
	Additional Tier 1 capital: instruments			
30	AT1 capital instruments and share premium (if applicable)	1,346		B2
31	of which: classified as equity under the Accounting Standards	1,346		
32	of which: classified as liabilities under the Accounting Standards	-		
33	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	832		B1
34	AT1 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	2		E3
35	of which: instruments issued by subsidiaries subject to phase out	-		
36	Additional Tier 1 capital before regulatory adjustments	2,179		
	Additional Tier 1 capital: regulatory adjustments			
37	Investments in own AT1 capital instruments	0		L
38	Reciprocal cross-holdings in AT1 capital instruments of financial institutions	-		
39	Capital investments in AT1 capital instruments of unconsolidated financial institutions	-		
ł	in which Reporting Bank does not hold a major stake			





Table 2 - Capital Components as at 30 Sep 2015

l	2 - Capital Components as at 30 Sep 2015		Amount	
			subject to Pre-Basel III	
	S\$ million	Amount	Treatment	Source
-	Investments in AT1 capital instruments of unconsolidated major stake companies	3	1	K2
	approved under s32 of Banking Act (including insurance subsidiaries)	0.704		
	National specific regulatory adjustments	2,781		
11A	PE/VC investments in the form of AT1 capital instruments, in excess of 20%	-	-	
44 D	of such capital investments			
	Any other items which the Authority may specify	2 704	-	
	Regulatory adjustments applied to AT1 Capital in respect of amounts	2,781		
	subject to pre-Basel III treatment of which: Goodwill, net of associated deferred tax liability	2,484		row 8 at 60%
	of which: Intangible assets, net of associated deferred tax liability	2,404	•	10W 6 at 60%
	of which: Deferred tax assets that rely on future profitability	237		row 10 at 60%
		237		10W 10 at 00 /8
	of which: Cash flow hedge reserve of which: Increase in equity capital resulting from securitisation transactions			
	of which: Unrealised fair value gains/losses on financial liabilities and derivative liabilities	-	-	
		-		
	arising from changes in own credit risk of which: Shortfall of TEP relative to EL under IRBA			
	of which: PE/VC investments in the form of ordinary shares, in excess of 20%	6		row 26A at 10%
	•	0		10W 20A at 10 /6
	of such capital investments	0	-	row 26B at 10%
	of which: PE/VC investments held beyond the relevant holding periods set out in	0		10W 20D at 10%
	MAS Notice 630			
-	of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	-		10 11001
	of which: Investments in ordinary shares of unconsolidated major stake companies	53		row 19 at 10%
	approved under s32 of Banking Act (incl insurance subsidiaries)			
	of which: PE/VC investments in the form of Tier 2 capital instruments, in excess of 20%	-		
	of such capital investments			
	of which: Investments in Tier 2 capital instruments of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (incl insurance subsidiaries)			
	Regulatory adjustments applied in calculation of AT1 Capital due to	-		
	insufficient Tier 2 Capital to satisfy required deductions			
	Total regulatory adjustments to Additional Tier 1 capital	2,784		
	Additional Tier 1 capital (AT1)	-		floored at zero
45	Tier 1 capital (T1 = CET1 + AT1)	25,254		
	Tier 2 capital: instruments and provisions			
	Tier 2 capital instruments and share premium (if applicable)	1,648		F2
	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	2,893		F1
	Tier 2 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	2		E4
_	of which: instruments issued by subsidiaries subject to phase out	-		
	Provisions	939		G
	Tier 2 capital before regulatory adjustments	5,483		
_	Tier 2 capital: regulatory adjustments			
	Investments in own Tier 2 instruments	-		L
	Reciprocal cross-holdings in Tier 2 capital instruments of financial institutions	-		
54	Capital investments in Tier 2 capital instruments of unconsolidated financial institutions	-		
	in which Reporting Bank does not hold a major stake			
55#	Investments in Tier 2 capital instruments of unconsolidated major stake companies	-	-	
	approved under s32 of Banking Act (including insurance subsidiaries)			
	National specific regulatory adjustments	298		
56A	PE/VC investments in the form of Tier 2 capital instruments, in excess of 20%	-	-	
	of such capital investments			
		_		
	Any other items which the Authority may specify	_		
	Any other items which the Authority may specify Regulatory adjustments applied to Tier 2 Capital in respect of amounts	298		
		298		
	Regulatory adjustments applied to Tier 2 Capital in respect of amounts	298		
	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment	298		row 26A at 50%
	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA	-		row 26A at 50%
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20%	-		row 26A at 50%
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments	30		
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments of which: PE/VC investments held beyond the relevant holding periods set out in	30		
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments of which: PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	30		
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments of which: PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 of which: Capital deficits in subsidiaries and associates that are regulated financial institutions of which: Investments in ordinary shares of unconsolidated major stake companies	30		row 26B at 50%
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment of which: Shortfall of TEP relative to EL under IRBA of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments of which: PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	30		row 26B at 50%





			Amount subject to	
	S\$ million	Amaunt	Pre-Basel III	Cauras
		Amount	Treatment	Source
	of which: Investments in AT1 capital instruments of unconsolidated major stake companies	1		row 40 at 30%
	approved under s32 of Banking Act (incl insurance subsidiaries)	200		
7	Total regulatory adjustments to Tier 2 capital	298		
8	Tier 2 capital (T2)	5,185		
9	Total capital (TC = T1 + T2)	30,439		
0	Total risk weighted assets	185,504		
	Capital ratios (as a percentage of risk weighted assets)			
1	Common Equity Tier 1 CAR	13.6%		
2	Tier 1 CAR	13.6%		
3	Total CAR	16.4%		
4	Bank-specific buffer requirement	6.5%		
5	of which: capital conservation buffer requirement	-		
6	of which: bank specific countercyclical buffer requirement	-		
7	of which: G-SIB buffer requirement (if applicable)	-		
8	Common Equity Tier 1 available to meet buffers	5.6%		
	National minima			
9	Minimum CET1 CAR	6.50%		
0	Minimum Tier 1 CAR	8.00%		
1	Minimum Total CAR	10.00%		
	Amounts below the thresholds for deduction (before risk weighting)			
2	Investments in ordinary shares, AT1 capital and Tier 2 capital of unconsolidated financial institutions in which the bank does not hold a major stake	543		
'3	Investments in ordinary shares of unconsolidated major stake companies	2,607		
	approved under s32 of Banking Act (including insurance subsidiaries)			
4	Mortgage servicing rights (net of related tax liability)	-		
5	Deferred tax assets arising from temporary differences (net of related tax liability)	-		
	Applicable caps on the inclusion of provisions in Tier 2			
6	Provisions eligible for inclusion in Tier 2 in respect of exposures	382		
	subject to standardised approach (prior to application of cap)			
7	Cap on inclusion of provisions in Tier 2 under standardised approach	234		row 50
8	Provisions eligible for inclusion in Tier 2 in respect of exposures	1,208		
	subject to internal ratings-based approach (prior to application of cap)	,		
9	Cap for inclusion of provisions in Tier 2 under internal ratings-based approach	706		row 50
	Capital instruments subject to phase-out arrangements			
	(only applicable between 1 Jan 2013 and 1 Jan 2022)			
0	Current cap on CET1 instruments subject to phase out arrangements	_		
1	Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)	_		
2	Current cap on AT1 instruments subject to phase out arrangements	1,504	-	
3	Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities)	1,504	-	
_		2.640	-	
4 5	Current cap on T2 instruments subject to phase out arrangements	3,649		
	Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)	-		

[#] These elements are subject to a more conservative definition relative to those set out under the Basel III capital standards.

